WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association for Cancer Research Dr Lana Kandalaft from the University of Pennsylvania in Philadelphia explained this was the first time a combination of dendritic cell vaccination and adoptive T-cell therapy had been used in ovarian cancer and that it was successful, even producing a complete remission in one patient and had few — if any — side effects. She discussed the therapy with Peter Goodwin.[audio:http://www.audiomedica.com/podcasting/oncology/130407LanaKandalaftPODCASTLoRes.mp3]
You may also like...
Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically 9 Aug, 2013 Breast Cancer: Combined Risk Assessment Prompts Treatment De-Escalation 16 Apr, 2018 New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer 15 Dec, 2007 “Total Therapy” Possible Cure For Multiple Myeloma? 26 Feb, 2008
- Previous story Blood test for free tumour DNA could guide breast cancer therapy
- Next story Treating HER 2 positive metastatic breast cancer without chemotherapy?
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014